(A) Overview of the cohort, including all de novo acute megakaryoblastic leukemia subtypes (n = 75), compared with mononuclear cells derived from the bone marrow (BM) of non-cancer donors under 18 ...

Discover the challenges of acute myeloid leukaemia linked to inflammatory cell death and the quest for effective therapies.

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

Acute myelogenous leukemia, or AML, remains one of the most aggressive blood cancers. Each year, around 44,000 people in the U.S. and Europe are diagnosed. For many, the road ahead is grim. Despite ...

CD37, a surface protein present on most acute myeloid leukemia (AML) blasts, demonstrates unique internalization properties that enable targeted drug delivery with minimal impact on normal blood cells ...

Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit ...

(A) The levels of the METTL3 protein in MV4.11, MOLM13, and NB4 cells treated with ZW27941 for 24 h detected by Western blot. METTL3 band intensity was normalized against ACTIN in each sample and DC50 ...

Despite major advances in immunotherapy—including the 2025 Nobel Prize in Physiology or Medicine recognizing advances in peripheral immune tolerance—progress against leukemia has remained limited.

Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...